Cyclin E

Cyclin E is a member of the cyclin family of proteins, which play a critical role in regulating the cell cycle. Cyclin E, in particular, is essential for the transition from the G1 phase to the S phase of the cell cycle, a process that is crucial for DNA replication and cell division. The activity of cyclin E is primarily regulated through its association with cyclin-dependent kinase 2 (CDK2), forming a complex that is necessary for the progression of the cell cycle.
Function[edit]
Cyclin E binds to CDK2 in the late G1 phase, activating the kinase activity of CDK2. This activation leads to the phosphorylation of several target proteins that are essential for DNA replication and the initiation of the S phase. The cyclin E-CDK2 complex thus plays a pivotal role in ensuring that cells are ready to enter the S phase, with all the necessary preparations for DNA synthesis being completed.
Regulation[edit]
The expression and activity of cyclin E are tightly regulated at multiple levels, including transcriptional, post-transcriptional, and post-translational modifications. Cyclin E levels are low in the early G1 phase and start to increase as the cell progresses towards the S phase. After its peak in the G1-S transition, cyclin E is degraded via the ubiquitin-proteasome pathway, ensuring that its activity is transient and tightly controlled.
Clinical Significance[edit]
Abnormalities in cyclin E expression and function have been implicated in the pathogenesis of various cancers. Overexpression of cyclin E can lead to uncontrolled cell proliferation, a hallmark of cancer. In particular, high levels of cyclin E have been observed in breast cancer, ovarian cancer, and colorectal cancer, among others. As such, cyclin E is considered a potential biomarker for cancer diagnosis and prognosis, as well as a target for therapeutic intervention.
Research[edit]
Research on cyclin E has focused on understanding its role in cell cycle regulation, its mechanisms of action, and its involvement in cancer. Studies have also explored the potential of targeting cyclin E in cancer therapy, either by inhibiting its activity or by modulating its expression levels. Additionally, research is being conducted to identify biomarkers associated with cyclin E overexpression in cancer, which could aid in early detection and treatment.

Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian